Venita DeAlmeida
Venita De Almeida started her career at Northwestern University, where she studied the GHRH receptor. Venita did her postdoctoral fellowship at Genentech and was instrumental in demonstrating the anti-tumor activity of multiple biologics that inhibited the Wnt signalling pathway. She continued Oncology research at Genentech, where worked on multiple ADC programs from target validation to identification of development candidates. Venita then joined Sutro Biopharma and was responsible for setting up preclinical development and led several development programs including the lead clinical program, STRO-002. Venita has since worked at 3T Biosciences and ALX Oncology where she led Program Development. During her career, Venita has worked on several biologics including fusion proteins, antibodies, ADCs and bispecifics; and has been involved in numerous INDs and clinical programs.